Contents

May 2012 • Volume 6 Number 2

3 Editorial comment
Tracy Crooks

4 Evolution not revolution in pharmacovigilance legislation
The new legislation is summarised and discussed, although the changes are still ongoing and raise a number of questions.
Sally Francis

7 The safety of excipients used in medicines for children
The safety of excipients used in paediatric products is a key consideration for those formulating medicines for children
Jennifer Walsh

10 The breast implant scandal and European Medical Device Regulations
The circumstances of the recent breast implant scandal are described in detail and the actions needed to prevent it in future are discussed.
Maria Donawa and Roger Gray

14 The cost of medical negligence in clinical trials
The risks involved in clinical trials can have severe consequences from the points of view of both the patients and the companies involved. Yet, medical negligence laws are both necessary and beneficial.
Ana Nicholls

16 Central aortic blood pressure – a better prediction of CV risk and outcomes?
There is increasing evidence that central aortic blood pressure may prove a better prognostic measure of cardiovascular risk than peripheral blood pressure.
C Venkata Ram